Aldeyra Therapeutics, Inc. (ALDX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ALDX Revenue Growth
ALDX Revenue Analysis (2013–2024)
As of May 8, 2026, Aldeyra Therapeutics, Inc. (ALDX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, ALDX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including OCUL (-12.8% YoY), and HALO (+37.6% YoY). Compare ALDX vs OCUL →
ALDX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALDXCurrent | $0 | - | - | - | |
 OCUL | $52M | -12.8% | +24.4% | -521.0% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
ALDX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-60,117,032 | - |
| 2023 | $0 | - | $0 | - | $-42,794,083 | - |
| 2022 | $0 | - | $0 | - | $-62,679,987 | - |
| 2021 | $0 | - | $0 | - | $-56,219,536 | - |
| 2020 | $0 | - | $-56,221 | - | $-34,666,755 | - |
| 2019 | $0 | - | $-96,305 | - | $-63,074,000 | - |
| 2018 | $0 | - | $-71,003 | - | $-39,699,000 | - |
| 2017 | $0 | - | $-37,849 | - | $-22,488,000 | - |
| 2016 | $0 | - | $-35,792 | - | $-18,696,000 | - |
| 2015 | $0 | - | $-18,778 | - | $-11,989,000 | - |
See ALDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALDX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALDX — Frequently Asked Questions
Quick answers to the most common questions about buying ALDX stock.
Is ALDX's revenue growth accelerating or slowing?
ALDX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ALDX's long-term revenue growth rate?
Aldeyra Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ALDX's revenue distributed by segment?
ALDX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.